Interstitial Granulomatous Dermatitis as an Adverse Reaction to Vedolizumab | Zendy

Katherine G. Beuerlein | Zendy; Elise Martin | Zendy; Lindsay C. Strowd | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Interstitial Granulomatous Dermatitis as an Adverse Reaction to Vedolizumab

Author(s) -

Katherine G. Beuerlein,

Elise Martin,

Lindsay C. Strowd

Publication year - 2022

Publication title -

cutis

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.289

H-Index - 53

eISSN - 2326-6929

pISSN - 0011-4162

DOI - 10.12788/cutis.0467

Subject(s) - medicine , vedolizumab , dermatology , rash , maculopapular rash , erythema , hypersensitivity reaction , complication , adverse effect , ulcerative colitis , pathology , immunology , surgery , disease

A 61-year-old woman with a medical history of ulcerative colitis (UC) developed an erythematous, mildly pruritic, maculopapular rash that was histologically consistent with reactive granulomatous dermatitis (RGD) with interstitial granulomatous dermatitis (IGD)-type features 1 week after vedolizumab infusion. Awareness of this complication is key to enhanced recognition and appropriate management as use of this medication becomes more prevalent.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research